Gregory Fraser
Stock Analyst at Truist Securities
(2.69)
# 1,908
Out of 5,241 analysts
39
Total ratings
57.14%
Success rate
16.33%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTMD biote | Maintains: Buy | $5 → $4 | $1.97 | +103.05% | 3 | Apr 16, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Hold | $77 → $90 | $78.01 | +15.37% | 11 | Oct 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $228.77 | +0.54% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $5.42 | +29.15% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $200 → $160 | $0.50 | +32,034.97% | 6 | Apr 30, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $11.93 | -41.32% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $56.37 | -48.55% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $17.58 | +440.39% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $6.50 | +176.92% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $21.32 | +87.62% | 2 | May 26, 2023 |
biote
Apr 16, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $1.97
Upside: +103.05%
ANI Pharmaceuticals
Oct 9, 2025
Maintains: Hold
Price Target: $77 → $90
Current: $78.01
Upside: +15.37%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $228.77
Upside: +0.54%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $5.42
Upside: +29.15%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $200 → $160
Current: $0.50
Upside: +32,034.97%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $11.93
Upside: -41.32%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $56.37
Upside: -48.55%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $17.58
Upside: +440.39%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $6.50
Upside: +176.92%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $21.32
Upside: +87.62%